Pacer Advisors Inc. Has $656,000 Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Pacer Advisors Inc. decreased its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 2.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,230 shares of the biotechnology company’s stock after selling 866 shares during the period. Pacer Advisors Inc.’s holdings in ADMA Biologics were worth $656,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ADMA. State Street Corp raised its position in shares of ADMA Biologics by 61.4% during the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock valued at $259,970,000 after buying an additional 4,945,063 shares during the last quarter. Geode Capital Management LLC raised its position in shares of ADMA Biologics by 2.6% during the third quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company’s stock valued at $107,606,000 after buying an additional 137,989 shares during the last quarter. Perpetual Ltd acquired a new position in shares of ADMA Biologics during the fourth quarter valued at about $62,300,000. Assenagon Asset Management S.A. raised its position in shares of ADMA Biologics by 2.7% during the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after buying an additional 92,281 shares during the last quarter. Finally, Lord Abbett & CO. LLC acquired a new position in shares of ADMA Biologics during the third quarter valued at about $61,858,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Price Performance

Shares of ADMA Biologics stock opened at $16.47 on Tuesday. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $3.89 billion, a price-to-earnings ratio of 58.82 and a beta of 0.75. ADMA Biologics, Inc. has a 1-year low of $5.02 and a 1-year high of $23.64. The firm’s 50-day moving average price is $18.10 and its two-hundred day moving average price is $17.61.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm had revenue of $119.84 million for the quarter, compared to analysts’ expectations of $107.25 million. During the same period in the prior year, the firm earned $0.01 earnings per share. On average, equities analysts predict that ADMA Biologics, Inc. will post 0.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on ADMA shares. Raymond James upped their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday, November 8th. HC Wainwright upped their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th.

Insider Activity

In other news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at $4,218,007.95. This represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 3.70% of the stock is owned by insiders.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.